theophylline has been researched along with Dysgeusia in 1 studies
Dysgeusia: A condition characterized by alterations of the sense of taste which may range from mild to severe, including gross distortions of taste quality.
Excerpt | Relevance | Reference |
---|---|---|
"Oral theophylline treatment improved taste and smell acuity in 6 patients after 2 to 12 months of treatment." | 2.77 | Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study. ( Henkin, RI; Minnick-Poppe, L; Schultz, M, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Henkin, RI | 1 |
Schultz, M | 1 |
Minnick-Poppe, L | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Smell in Covid-19 and Efficacy of Nasal Theophylline[NCT04789499] | Phase 2 | 51 participants (Actual) | Interventional | 2021-03-15 | Completed | ||
Helping Olfaction and Nutrition On Renal Replacement[NCT02479451] | Phase 2 | 12 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
A Randomized, Double-Blinded, Placebo-Controlled Trial to Determine The Safety and Efficacy of CYR-064[NCT06019000] | Phase 2 | 150 participants (Anticipated) | Interventional | 2023-09-26 | Recruiting | ||
Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)[NCT05216614] | Phase 2 | 0 participants (Actual) | Interventional | 2021-12-14 | Withdrawn (stopped due to Unable to obtain investigational product) | ||
Smell in COVID-19 and Efficacy of Nasal Theophylline 3[NCT05947643] | Phase 2 | 240 participants (Anticipated) | Interventional | 2022-11-22 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The SF-36 is a well-established 36-item questionnaire evaluating physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. This test allows us to study the overall quality of life for those suffering from COVID-19 related OD. There is no single overall score for SF-36. The SF 36 generates 8 subscales with scores ranging from 0 (worst) to 100 (best). General health domain scores are reported here. (NCT04789499)
Timeframe: Baseline assessment
Intervention | score on a scale (Median) |
---|---|
Theophylline | 75 |
Placebo | 80 |
Questionnaire for Olfactory Dysfunction (QOD) assesses health-related quality of life of participants based on four factors such as eating, mental health, social interactions, or fear of dysfunction.. The survey also includes questions on parosmia, a phenomena of COVID-related OD. The QOD consists of 17 statements that participants score from 0-3, resulting in a total score from 0 to 51. Higher scores reflect better olfactory-specific QOL. (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline
Intervention | score on a scale (Median) |
---|---|
Theophylline | 0.86 |
Placebo | 1.43 |
The ODOR is a 28-item QOL instrument with a total score ranging from 0 to 112 points. Higher scores indicate worse QOL with higher degree of dysfunction and limitation. A decrease of 15 or more points is deemed to be a clinically significant improvement in QOL. (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups
Intervention | score on a scale (Median) |
---|---|
Theophylline | -6.5 |
Placebo | -4.5 |
"UPSIT 0-40 with higher scores indicating better smell.~This test is an objective, clinically validated 40-question forced-choice odor identification test where microencapsulated odorants on a strip are released by scratching. Out of a total of 40 points, normosmia is defined as ≥34 for males and ≥35 for females, and an increase in ≥4 points will be deemed a clinically significant improvement in symptoms." (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline
Intervention | score on a scale (Median) |
---|---|
Theophylline | 3 |
Placebo | 0 |
"UPSIT 0-40 with higher scores indicating better results.~The response rate defined as the number of participants in each group self-reporting of at least slightly better improvement in the Clinical Global Improvement Scale at 6 weeks post intervention as compared to baseline, devided by the total number of participants in that specific group. The CGI-Improvement Scale has seven response options (from 1 as Very Much Improved to 7 as Very Much Worsened) for answers to the question Compared to your sense of smell before you started the nasal irrigations, how would you rate your sense of smell now . Participants reporting 3 as Minimally Improved, 2 as Much Improved, or 1 as Very Much Improved in the CGI-I will be deemed responders to treatment, and the rate of responders will be compared between the two arms." (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups
Intervention | percentage of participants (Number) |
---|---|
Theophylline | 59 |
Placebo | 43 |
1 trial available for theophylline and Dysgeusia
Article | Year |
---|---|
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |
Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Dru | 2012 |